Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,053 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Dermatitis, Atopic, Pruritus
Interventions: 3% kanuka oil; Other
Lead sponsor: Nexgen Dermatologics, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boynton Beach, Florida

Conditions: Dermatitis, Atopic
Interventions: Combination therapy GSK2894512 Cream A + GSK2894512 Cream B, Combination therapy Vehicle Cream A + Vehicle Cream B; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Angioedema
Interventions: Not listed
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Atopic Dermatitis
Interventions: MM36 topical ointment, 1%; Drug
Lead sponsor: Medimetriks Pharmaceuticals, Inc; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Fremont, California • Irvine, California • San Diego, California + 7 more

Conditions: Hereditary Angioedema
Interventions: rhC1INH, Placebo (Saline); Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 13 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 15
States / cities: Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more

Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer With Bone Involvement, Bone Metastases in Subjects With Advanced Breast Cancer, ER-Positive HER2-Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Hormone-sensitive Metastatic Breast Cancer, Hormone-Sensitive Breast Cancer
Interventions: RYZ101, Standard of Care Endocrine Therapy; Drug
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: Not listed
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 25
States / cities: Phoenix, Arizona • Irvine, California • San Diego, California + 21 more

Conditions: Food Allergy in Children
Interventions: Skin tape stripping, Skin barrier assessment, Blood draw; Diagnostic Test · Device
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atopic Dermatitis, Atopic Disorders, Eczema, Atopic Eczema
Interventions: Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 1 Day to 63 Days
Enrollment: 1,260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Denver, Colorado • Durham, North Carolina • Portland, Oregon + 1 more

Conditions: Breast Cancer
Interventions: Molecular Breast Imaging (MBI), CZT semiconductor detectors; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections
Interventions: gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: RPT193, Placebo; Drug
Lead sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 13
States / cities: Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more

Conditions: Dermatitis, Atopic
Interventions: LY3471851, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: North Little Rock, Arkansas • Encinitas, California • Fremont, California + 17 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Scottsdale, Arizona • Tucson, Arizona • Lomita, California + 38 more

Conditions: Atopic Dermatitis
Interventions: Fluocinonide cream; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Atopic Dermatitis
Interventions: Fluticasone propionate 0.05% lotion; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 3 Months to 12 Months
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 10
States / cities: Poway, California • San Diego, California • Miami, Florida + 7 more

Conditions: Atopic Dermatitis
Interventions: omalizumab; Biological
Lead sponsor: Stanford University; Other
Eligibility: 4 Years to 25 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Stanford, California

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 98
States / cities: Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 84 more

Conditions: Atopic Dermatitis
Interventions: Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 1 Year to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hereditary Angioedema
Interventions: KVD900 150 mg, KVD900 300 mg, KVD900 600 mg; Drug
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 7 more

Conditions: Dermatitis, Atopic
Interventions: DSXS; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Atopic Dermatitis, Eczema
Interventions: Pre-Treatment with Dial liquid antibacterial soap, Control; Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Atopic Dermatitis, Eczema, Asthma, Food Allergies, Allergic Rhinitis
Interventions: Lipikar Balm AP; Drug
Lead sponsor: Cosmetique Active International; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Canton, Michigan • Fort Gratiot, Michigan

Conditions: Food Hypersensitivity
Interventions: Not listed
Lead sponsor: ORA, Inc.; Industry
Eligibility: 5 Years to 35 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Soak and smear, Dry Smear; Other
Lead sponsor: Yale University; Other
Eligibility: 2 Weeks to 18 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis

A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream

Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Skin Characteristics of Parents of Food Allergic Pediatric Patients

A Community-based Assessment of Skin Care, Allergies, and Eczema

Pre-biopsy With Dynamic Acquisitions

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

A Study of LY3471851 in Participants With Eczema

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

Cutivate Lotion HPA Axis Pediatric Study

Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Dupilumab De-escalation in Pediatric Atopic Dermatitis

Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival

Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis

Food Allergy Challenge Diagnostic Study

A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis